Figure 8.

PTTG1, UBE2C and ZWINT as the targets for anti-cancer drugs. A. Alteration in the frequency of six genes mutations in HCC was analyzed using cBioPortal. The data suggested that the six genes were altered in 93 (26.96%) of 345 patients. B. OncoPrint was used to provide a visual summary of alterations across a set of HCC samples. PTTG1 was altered in approximate 11%, and the main type of alteration was mRNA upregulation. C. A network contained 56 genes (6 real hub genes and 50 most variant genes). D. TP53 was significantly vital in the network. E, F. The relationship between anti-cancer drugs and hub genes was explored, which showed that CCNB1, CDK1, and AURKA were targets of cancer drugs. However, there was no drug targeting to the rest of the three hub genes, PTTG1, UBE2C, and ZWINT, which might serve as novel therapeutic targets for patients with HCC. Furthermore, qPCR and western blot assays suggested that PTTG1, UBE2C, and ZWINT were highly expressed in MHCC97H, Hep3B, and HuH7 cell lines. HCC, hepatocellular carcinoma.